Modality
mAb
MOA
PD-L1i
Target
PD-L1
Pathway
Neuroinflam
Hemophilia A
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
Mar 2024
→ Apr 2025
Phase 1Current
NCT08316929
1,212 pts·Hemophilia A
2024-03→2025-04·Active
1,212 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-2811mo agoInterim· Hemophilia A
Trial Timeline
Q2Q3Q42025Q2
P1
Active
Catalysts
Interim
2025-04-28 · 11mo ago
Hemophilia A
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08316929 | Phase 1 | Hemophilia A | Active | 1212 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |